A must-see CME symposium at the 44th Annual Meeting of the
European Society for Blood and Marrow Transplantation (EBMT).

Register Now

Sunday, March 18, 2018

Registration & Lunch
12:00 PM – 12:30 PM
CME Symposium / Q&A Session
12:30 PM – 2:00 PM

CCL – Lisbon Congress Centre
Auditorium I
Praça das Indústrias, 1300-307
Lisbon, Portugal

12:00 PM – 12:30 PM Registration & Lunch
12:30 PM – 12:35 PM Welcome and Introductions
  Per Ljungman, MD, PhD
12:35 PM – 12:55 PM CMV in HSCT: Challenges and Unmet Needs
  Per Ljungman, MD, PhD
12:55 PM – 1:15 PM Update on Current Management of CMV in HSCT
  Johan Maertens, MD, PhD
1:15 PM – 1:35 PM Update on Emerging Therapies for CMV in HSCT
  Genovefa Papanicolaou, MD
1:35 PM – 2:00 PM Clinical Cases, Panel Discussion, and Audience Q&A
  All Faculty


Per Ljungman, MD, PhD (Chair)
Senior Physician, Department of Cellular Therapy and Allogenic Stem Cell Transplantation
Karolinska University Hospital
Professor (em), Division of Hematology, Department of Medicine Huddinge
Karolinska Institute
Stockholm, Sweden

Johan Maertens, MD, PhD
Consultant Hematologist
Department of Hematology
UZ Gasthuisberg Leuven
Leuven, Belgium

Genovefa Papanicolaou, MD
Attending Physician, Director Clinical Trials
Infectious Disease Service
Memorial Sloan-Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY (USA)

This activity has been designed to meet the educational needs of clinicians who manage cytomegalovirus (CMV) infection in patients who undergo hematopoietic stem cell transplant (HSCT).

After participating in this educational activity participants should be better able to:

  • Implement prophylactic and preventive anti-CMV therapy in at-risk transplant patients as recommended by the current evidence base
  • Promptly diagnose transplant patients with CMV infection and disease, using new and emerging assays and tools
  • Apply clinical trial data for new and emerging treatment options to manage transplant patients infected with CMV, including those with resistant or refractory disease
  • Identify and address adverse events of agents used for prophylaxis and treatment of CMV infection and disease

An application has been made to the UEMS EACCME® for CME accreditation of this event.

The “Conflict of Interest Disclosure Policy” of Albert Einstein College of Medicine requires that faculty participating in any CME activity disclose to the audience any relevant relationship(s) with a pharmaceutical, product, or device company. Any presenter whose disclosed relationships prove to create a conflict of interest with regard to their contribution to the activity, will not be permitted to present.

Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. Albert Einstein College of Medicine, CCME staff, has no relevant conflicts of interest with commercial interests related directly or indirectly to this educational activity.

There is no fee for this educational activity.

Jointly provided by RMEI Medical Education, LLC, Albert Einstein College of Medicine, and Montefiore Medical Center.

Register Now

This educational activity is supported by an independent medical educational grant from Shire.



Facebook Twitter

Additional educational activities offered by RMEI Medical Education, LLC can be found at www.RMEI.com or by calling toll-free (866) 770-RMEI.